A recent randomized clinical trial showed that the weekly administration of paclitaxel with alisertib based on elevated AURKA expression significantly improved the PFS of patients with metastatic HR-positive and HER-2-negative breast cancer compared with the use of paclitaxel alone; the efficacy of this treatment in patients with TN breast cancer was not examined due to late enrollment [135]. The gene discussed is ERBB2; the disease is breast carcinoma.